Physician profile
Jodi L Fields
NPI 1265830624
$4,075.56
in general payments reported to CMS, 2019-2025
33 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,882 · 2022: $2,012 · 2023: $165 · 2024: $15.81.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $181.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $181.30 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $753.74 | 2021-2022 | |
| Novo Nordisk INC | $455.19 | 2021-2022 | |
| Glaxosmithkline, LLC. | $393.32 | 2021-2023 | Shingrix |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $243.56 | 2021-2023 | Xifaxan |
| Amarin Pharma, INC. | $235.87 | 2021-2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $225.63 | 2022 | |
| Abbott Laboratories | $191.20 | 2021-2022 | |
| Lilly USA, LLC | $184.88 | 2022 | |
| Daiichi Sankyo INC. | $170.62 | 2021-2022 | |
| Novartis Pharmaceuticals Corporation | $156.00 | 2021-2022 | |
| Biohaven Pharmaceutical Holding Company LTD. | $143.07 | 2022 | |
| Janssen Pharmaceuticals, INC | $120.18 | 2021-2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $112.29 | 2021-2022 | |
| Relievant Medsystems, INC. | $81.12 | 2023 | Intracept |
| Amgen INC. | $80.08 | 2021-2022 |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $71.59 | 2021-2022 | |
| Astrazeneca Pharmaceuticals LP | $53.99 | 2021 | |
| Biohaven Pharmaceuticals, INC. | $49.20 | 2021 | |
| Collegium Pharmaceutical, INC. | $47.22 | 2023-2024 | Belbuca, Xtampza |
| Jazz Pharmaceuticals INC. | $40.54 | 2021 | |
| Astellas Pharma US INC | $40.27 | 2021 | |
| Ardelyx, INC. | $31.38 | 2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $28.73 | 2021 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $23.41 | 2022 | |
| Boston Scientific Corporation | $21.55 | 2022 | |
| Azurity Pharmaceuticals, INC. | $18.90 | 2023 | Horizant |
| Merck Sharp & Dohme LLC | $17.17 | 2021 | |
| Shield Therapeutics INC | $16.23 | 2022 | |
| Ultragenyx Pharmaceutical INC. | $16.12 | 2021 | |
| Sanofi-Aventis U.S. LLC | $14.51 | 2021 | |
| Idorsia Pharmaceuticals US INC | $13.08 | 2022 | |
| Medtronic, INC. | $12.68 | 2022 | |
| Adlon Therapeutics L.P. | $12.24 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jodi Fields listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.